INTRODUCTION
Alzheimer's disease (AD) is a progressive and incurable disorder associated with a progressive decline of memory. This senile dementia is characterized by neuronal loss, synaptic degeneration, presence of extracellular amyloid-β-peptide (Aβ) deposits and intracellular neurofibrillary tangles. Amyloid precursor protein (APP) is cleaved into Aβ peptide, and two main Aβ isoforms exist (Aβ and Aβ ). Aβ peptide can oligomerize to form soluble oligomers (such as dimers, trimers or dodecamers [Aβ *56] ) and aggregate to form protofibrils, fibrils and, then, amyloid plaques (1, 2) . Beside these pathological hallmarks, Aβ plaques are surrounded by microglia and astrocytes (3) . Microglia, the mononuclear phagocytes of the brain (4) , are found around Aβ plaques of brain sections taken from AD patients (5, 6) and AD mouse models (7) (8) (9) . Both resident microglia and newly differentiated cells that are derived from the bone marrow are frequently associated with Aβ deposits. Of interest, bone marrow-derived microglia restrict amyloid burden in the brain because of their more efficient phagocytic properties compared with their resident counterparts (7) .
Microglia originate in part from hemato poietic cells and more particularly from monocytes (10) (11) (12) 
Gr1
-Ly6-C low subset (13) . These chemokine receptors bind specific ligands and allow monocyte migration and attraction to their sites of production (14) (15) (16) . CC-chemokine receptor 2 (CCR2) is found on the surface of monocytes and of a small percentage of T cells (17, 18) . Recently, it was shown that hematopoietic stem cells (HSCs) and hematopoietic progenitor cells express CCR2 (19) where it mediates the migration of mature monocytes from bone marrow into the blood (20) (21) (22) . This receptor also allows recruiting of circulating monocytes (22) and of HSCs and hematopoietic progenitor cells (19) to inflammatory tissues in mice. This occurs in mouse models of multiple sclerosis (23) , in hippocampus at sites of axonal injury (24) and in systemic organs during inflammation (25) . CCR2 can bind to five proinflammatory chemokines (monocyte chemoattractant protein [MCP]-1 to MCP-5), but its main physiological ligand is MCP-1 (also known as CCL2) (26) . Several cell types express MCP-1, such as endothelial cells (27, 28) , astrocytes (29, 30) and microglia (31) (32) (33) . In addition to the property of binding only CCR2, MCP-1 is upregulated in the brain of both AD patients (34, 35) and AD transgenic mice (7, 36, 37) . Indeed, Aβ induces MCP-1 production in cultures of microglia (31, 32) and astrocytes (29) , and CCR2 deficiency accelerates the progression of AD hallmarks in two AD mouse models, namely APP Tg2576 mice (36) and APP Swe /PS1 (37) . CCR2 deficiency in APP Swe (Tg2576) accelerates early disease progression and induces the premature death of the mice (36) . In addition, APP Swe / PS1/CCR2 -/-mice exhibit earlier and aggravated mnesic impairment and an increase of soluble Aβ and plaqueassociated microglia, which express, more importantly, transforming growth factor (TGF)-β1 and TGF-β receptors (37 We show that CCR2-competent monocytes prevent disease onset as well as counteract AD pathology.
MATERIALS AND METHODS

Animals
Transgenic mice. We used adult male C57BL/6 mice (wild-type [WT]), green fluorescent protein (GFP) [CByJ.B6-
Tg(CAG-EGFP)1Osb/J], CCR2
-/-(B6.129S4-Ccr2tm1Ifc/J) and APP transgenic mice (APP Swe /PS1) harboring the chimeric mouse/human β-amyloid precursor protein (APP695swe) and the human presenilin I (A246E variant) under the control of independent mouse prion protein promoter elements [B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J]. APP Swe /PS1 mice were bred with the CCR2 -/-mouse strain for at least three generations to generate APP Swe / PS1/ CCR2 -/-triple transgenic animals. All mouse strains were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained in a C57BL/6J background. All newborn pups were genotyped as described in The Jackson Laboratory protocol. Mice were used to study behavioral and biochemical modifications at 6 months of age. Mice were housed three to five per cage and acclimated to standard laboratory conditions (12-h light, 12-h dark cycle; lights on at 07:00 and off at 19:00) with free access to mouse chow and water. Animal breeding and experiments were conducted according to the Canadian Council on Animal Care guidelines, as administered by the Laval University Animal Care Committee. Chimeric mice: irradiation and bone marrow transplantation. Male APP Swe /PS1 and APP Swe /PS1/CCR2 -/-mice, 2.5-3 months of age, were exposed to 10 Gy total-body irradiation using a 60 Co source (Theratron-780 Irradiated mice transplanted with the cell suspension were housed in autoclaved cages and treated with antibiotics (0.2 mg trimethoprim and 1 mg sulfamethoxazole/mL drinking water given for 7 d before and 2 wks after irradiation). Animals (n = 77) were submitted to behavioral tests 3 months after transplantation and then killed for brain analyses. Production and femoral injection of lentiviral vectors. Lentivirus construction was performed as previously described (39), using a ViraPower T-Rex Lentiviral Gateway Vector kit (Invitrogen, Burlington, ON, Canada). The vector pLenti4/TO/V5-DEST was modified to visualize transduction. The Zeocin resistance cassette was replaced by the enhanced GFP coding region with a phosphoglycerate kinase promoter. The insert was amplified using the pSuperior vector as a template (OligoEngine) (forward, 5′-CACAA GTGGC CTCGAGCCTC GCACACATTC CACATCCAC-3′; reverse, 5′-CTTGT TCAATCATGGTACCT CTAGCCTTAA GTTCGAGAC-3′) and was inserted in the pLenti4/TO/V5-DEST between the XhoI and KpnI restriction sites, forming the pLenti/GFP vector. The CCR2 coding sequence was amplified by polymerase chain reaction (PCR) from a cDNA brain library and cloned in the pENTR4 vector using the XmnI and XhoI restriction sites of the polylinker (forward, 5′-ATGGA AGACA ATAATATGTTACCTC-3′; reverse, 5′-CAAACTGTCACTCGAGTTAC AACC-3′; GenBank accession number NM_009915). The CCR2 coding sequence was transferred onto the pLenti/GFP downstream of the cytomegalovirus promoter by homologous recombination, forming the pLenti/GFP/CCR2. To prepare the lentivirus, 293T cells (a gift from L Vallières, Laval University, Québec, Canada) were transfected with pLenti/GFP/CCR2, pLPI, pLP2 and pLP-vesicular stomatitis virus protein G (20 μg per plasmid) using the calcium chloride technique. Lentiviruses were concentrated by ultracentrifugation (50, control lentivirus (pLenti/GFP) or pLenti/GFP/CCR2 were tested at 6 months of age for spatial learning and memory and then killed for brain analyses (n = 59).
Behavioral Analyses
Water T-maze. Mice were tested during the "light-on" phase of the day. Mice of each group were tested in a same session. The behavioral experimenter was blind to the genetic and treatment status of animals. To assess hippocampaldependent spatial learning and memory, mice were trained in the water T-maze task. In this paradigm, we evaluate the mouse's ability to remember the spatial location of a submerged platform. The T-maze apparatus (stem length, 64 cm; arm length, 30 cm; width, 12 cm; wall height, 16 cm) was made of clear fiberglass and filled with water (23 ± 1°C) at a height of 12 cm. A platform (11 × 11 cm) was placed at the end of the target arm and was submerged 1 cm below the surface. The acquisition phase allows evaluation of the animals for left-right spatial learning. During the first two trials, platforms were placed on each arm of the maze to test the spontaneous turning preference of the mouse. After these two trials, the least chosen arm was reinforced by the escape platform. The mice were placed in the stem of the T-maze and were left to choose swimming either left or right until they found the submerged platform and escaped to it, for a maximum of 60 s. After reaching the platform, the mice remained on it for 20 s and were then immediately placed back into the maze. If the animals did not find the platform within this limit, they were gently guided onto it. Repeated trials were presented on the same day up to a maximum of 48 trials. A rest period of at least 10-15 min intervened between each block of 10 trials. A mouse was considered to have learned the task when it made no errors in a block of five consecutive trials. The reversal learning phase was then conducted 48 h later. During this phase, the same protocol was repeated, except that mice were trained to find the escape platform on the side opposite to where they had learned in the acquisition phase. The number of trials to reach the criterion (five of five correct choices made on consecutive trials) was measured as well as the latency to find the escape platform.
Passive avoidance test. Because the animals had a natural tendency to prefer dark environments, they were also evaluated in their retention of nonspatial memory for a one-trial passive avoidance task. The passive avoidance apparatus (Ugo Basile) was divided into two sections, one illuminated (the start compartment) and one dark (escape compartment). The floor of each compartment contained a grid, with only the dark compartment being electrified by a generator. On the training day, mice were placed into the lighted compartment for a 60-s acclimation period. The guillotine door was then opened, and the latency to enter the dark side was recorded. Immediately after entering the dark compartment, the door was closed and an electric shock (0.5 mA for 2 s) was delivered. The mouse was kept in the dark compartment for 10 s before being returned to its home cage. On the next day, the mice were placed again in the light compartment, and the step-through latency to enter the dark side was measured for up to 300 s.
Tissue Analyses
Transgenic, chimeric or lentivirustreated mice were anesthetized under isofluorane, and blood was drawn via cardiac puncture before decapitation. Brains were rapidly removed from the skulls and placed in cold phosphate-buffered saline solution. Hemibrains were then separated and olfactory bulbs and cerebellum were removed. One hemibrain was rapidly frozen in liquid nitrogen and stored at -80°C for protein analysis. The other was postfixed for 2-4 d in 4% paraformaldehyde, pH 9.5, at 4°C and then placed in a paraformaldehyde solution containing 10% (w/v) sucrose overnight at 4°C. The frozen brains were mounted on a microtome (Reichert-Jung) and cut into 25-μm coronal sections. Slices were collected in cold cryoprotectant solution (0.05 mol/L sodium phosphate buffer, pH 7.3, 30% ethylene glycol and 20% glycerol) and stored at -20°C until performing immunocytochemistry or in situ hybridization histochemistry.
In situ hybridization and immunohistochemistry. Every twelfth section of brain slices, starting from the end of the olfactory bulb to the end of the cerebral cortex, was mounted on Colorfrost/Plus microscope slides (Fisher Scientific, Ottawa, ON, Canada) for transgenic and chimeric mice (6 months of age, n = 5-12 per group). In situ hybridization for the histochemical localization of CX 3 CR1, TGF-β1 and TGF-β receptors R1 and R2 was performed using 35 S-labeled cRNA probes. Plasmids were linearized, and sense and antisense cRNA probes were synthesized with the appropriate RNA polymerase, as described in Table 1 . Riboprobe synthesis and preparation and in situ hybridization were performed according to a previously described protocol (40) (41) (42) (43) . For each transcript, the expression level was estimated by qualitative analysis using a Nikon Eclipse 80i microscope over the wholebrain sections for 5-10 animals/ group.
Dual labeling combining immunocytochemistry and in situ hybridization was performed as described previously (40, 42) to localize CX 3 CR1 transcripts in GFP cells. We used polyclonal rabbit anti-green fluorescent protein (GFP, 1:2,000, Molecular Probes; anti-rabbit biotin-conjugated, 1:1,500, Jackson ImmunoResearch (West Grove, PA, USA).
All images were captured using a Nikon Eclipse 80i microscope equipped with a digital camera (QImaging), processed to enhance contrast and sharpness using Adobe Photoshop 7 (Adobe Systems), and then assembled using Adobe Illustrator (Adobe Systems). The images depicted by the different panels are representative of the signal detected on the slides for each group of mice.
Stereological analysis. An observer who was blind to the treatment status of the material did all quantitative histological analyses. To count Aβ plaques and plaque-associated microglia, sections of APP Swe /PS1 and APP Swe /PS1/CCR2 -/-mice or chimeric mice (6 months of age, n = 6-15 per group) were immuno stained for Aβ (polyclonal mouse anti-Aβ 6E10, 1:3,000; Covance, Princeton, NJ, USA) and ionized calcium binding adaptor molecule 1 (iba-1) proteins with 4′,6′-diamidino-2-phenylindole as previously reported (7, 39) . Four sections were chosen for hippocampus/cerebral cortex at -1.70, -1.94, -2.46 and -2.92 mm from the bregma according to a stereotaxic atlas (44 [Paxinos and Franklin] ). Unbiased stereological analysis was performed as described previously (7, 39, 45) . Briefly, the contours of the hippocampus and the cortex areas were traced as virtual overlays on the steamed images, and areas were calculated. The area occupied by all Aβ-labeled plaques was determined as well as the plaque-associated microglia number in each structure.
Protein extraction and detection of total Aβ levels by Western blot. Proteins from hemiforebrains were extracted using a modified version of the procedure published by Lesne et al. (1) . All manipulations were done on ice to minimize protein degradation. One hemiforebrain was placed in a 1-mL syringe with a 20-gauge needle. A total of 500 μL buffer A (50 mmol/L Tris-HCl, pH 7.6,
and protease inhibitor cocktail) were added, and 10 up-and-down strokes were made to homogenize the tissue, followed by a 5-min centrifugation at 830g at 4°C. The supernatant (extracellular protein-enriched fraction) was then collected and frozen at -80°C. The insoluble pellet was suspended in 500 μL TNT buffer (Buffer B; 50 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl, 0.1% Triton X-100, 1 mmol/L PMSF and protease inhibitor cocktail), followed by a 90-min centrifugation at 15,588g at 4°C. The supernatant (cytoplasmic protein-enriched fraction) was then collected and frozen at -80°C. The pellet was suspended in 500 μL buffer C (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.5% Triton X-100, 1 mmol/L EGTA [ethyleneglycotetraacetic acid], 3% SDS, 1% deoxycholate, 1 mmol/L PMSF and protease inhibitor cocktail) and incubated at 4°C, 0.23g, for 1 h. Samples were centrifuged for 90 min at 15,588g at 4°C, and the supernatant (membrane protein enriched fraction) was collected and frozen at -80°C. Protein concentration of each fraction was determined using the Quantipro bicinchoninic acid assay kit (Sigma) according to the manufacturer's protocol.
For total Aβ detection, 10-20 μg extracellular, cytoplasmic and membrane protein fractions were separated on a precast 10-20% SDS polyacrylamide Tris-Tricine gel (Bio-Rad). Resolved proteins were then transferred onto polyvinylidene fluoride (PVDF) membranes (PerkinElmer, Woodbridge, ON, Canada) and detected by Western blotting. Blots were probed with a mouse anti-amyloid β protein monoclonal antibody clone 6E10 (1:1,000; Covariance) in 1 mol/L Tris-HCl, pH 8.0, 5 mol/L NaCl, 5% skim milk and 0.05% Tween 20. Blots were visualized with antimouse secondary antibody tagged with horseradish peroxidase (1:1,000; Jackson ImmunoResearch) using enhanced chemiluminescence (PerkinElmer). Membranes were stripped in 25 mmol/L glycine-HCl, pH 2.0, containing 1% SDS to allow β-actin revelation, first using a mouse β-actin antibody (MAB1501, 1:5,000; Millipore Bioscience Research Reagents) and then a goat anti-mouse peroxidase-conjugated secondary antibody (1:1,000; Jackson ImmunoResearch).
Quantification was done by determining the integrative density of the bands using a gel imaging system (Agfa Arcus II scanner with NIH ImageJ software, version 1.32j, for quantitation) with subtraction of background values. Optical values were normalized according to the actin loading control. Results are expressed as the mean ± standard error of the mean (SEM).
Fluorescence-Activated Cell Sorting (FACS) Analyses
Chimerism was confirmed by fluorescence-activated cell sorting (FACS) of red blood cell-lysed blood. Briefly, whole blood was taken from the facial vein and quickly suspended, and cells were washed several times in DPBS + 5% goat serum. Phycoerythrin (PE)-conjugated CD11b antibody (Cedarlane) was then added, and cells were washed again in DPBS + 5% goat serum. Red blood cells were then lysed with hemolysin according to the manu- In lentiviral treatment, FACS analysis was performed on red blood cell-lysed blood. As previously described, whole blood was taken from the facial vein and was only lysed just before being analyzed by FACS to determine GFP fluorescence.
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To analyze the population of monocytes, anticoagulated whole blood was taken from the facial vein and quickly suspended, and cells were washed in DPBS + 4% fetal bovine serum. Cells, suspended in DPBS + 2% fetal bovine serum, were first incubated on ice for 15 min with purified rat anti-mouse CD16/CD32 (Mouse BD Fc Block, BD Biosciences). The mix was then incubated on ice with PE-Cy7-conjugated CD11b antibody (eBioscience), allophycocyaninconjugated CD115 antibody (eBioscience), FITC Ly6-C antibody (BD Biosciences) and PerCP-Cy5.5™-conjugated Gr1 antibody (Cedarlane) for 35 min. Cells were washed again in DPBS + 2% fetal bovine serum. Red blood cells were lysed with hemolysin according to the manufacturer's protocol (Beckman Coulter, Mervue, Galway, Ireland), and cells were washed with DPBS and resuspended in equal volumes of DPBS. For CCR2 detection, washed cells were first incubated on ice with monoclonal antibody MC-21 (anti-CCR2) for 60 min (17) . After washing, cells were incubated for 60 min on ice with a biotin-labeled anti-rat polyclonal antibody (BD Biosciences). Cells were washed again and incubated with purified rat anti-mouse CD16/CD32 on ice for 15 min, before adding PerCP™-labeled streptavidin antibody (BD Biosciences) and the combination of directly conjugated antibodies as described previously (17) . Cells were analyzed using a two-laser and six-color FACS Canto II flow cytometer, and data acquisition was done with BD Facs Diva software (version 6.1.2, BD Biosciences). Cells were then sorted according to the respective fluorescent antibodies. Results were analyzed using Flow Jo software (Tristar).
Statistical Analyses
Results are expressed as the mean ± SEM. Statistical analysis was performed by one-or two-way analysis of variance (ANOVA), followed by the appropriate test procedure, using Bonferroni, Dunnett or Tamhane tests as post hoc comparisons (SPSS software). Data were analyzed using standard two-tailed unpaired t tests for the comparison between two groups.
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The relationship between spatial working memory and levels of soluble Aβ species (extracellular-or membrane-associated proteins) were determined in two groups of animals. evidenced by the decreased number of trials (7.6 ± 1.4 versus 14.5 ± 1.5 for APP Swe / PS1, P < 0.05, and 9.8 ± 0.5 versus 23. . One-way ANOVA was performed using the Bonferroni or Tamhane post hoc test. Scale bar 500 μm.
, ; P < 0.01 and P < 0.05, respectively) ( Figure 2H ), plaque density and the percentage of area occupied by plaques in hippocampus and cortex remained similar in APP Swe /PS1 or APP Swe / PS1/CCR2 -/-mice harboring WT GFP or CCR2 -/-BMCs ( Figure 2 ). Therefore, no correlation was observed between mnesic deficit and Aβ plaque burden. As reported in the literature, memory deficits correlate more strongly with cortical levels of soluble Aβ species than with insoluble Aβ plaque burden in AD patients (46, 47) and mouse models of AD (1, 48) . Each Aβ species ratio (Aβ/β-actin) is represented for extracellular (B) and membraneassociated proteins (E). Lower levels of soluble extracellular and membrane-associated Aβ species were found in mice harboring WT BMCs, whereas Aβ oligomer levels increased in mice transplanted with CCR2-deficient BMCs. Correlations were determined between spatial memory decline (water T-maze test) and soluble Aβ species in extracellular (C) and membraneassociated (F) fractions. Results are expressed as the mean ± SEM; n = 4-5; *P < 0.05, **P < 0.01 and *** P < 0.001 versus APP Swe /PS1; # P < 0.05 versus GFP → APP Swe /PS1. One-way ANOVA was performed using Dunnett or Tamhane post hoc tests; for the Dunnett test, the control group was GFP → APP Swe /PS1 mice. Correlation was estimated by the Spearman correlation coefficient. OD, optical density; , APP Swe /PS1; ,GFP → APP Swe /PS1; , CCR2 -/-→ APP Swe /PS1.
Aβ levels of APP Swe / PS1/ CCR2 -/-mice ( Figures 3A, B, and 4A , B, respectively). A positive and strong correlation was shown between memory deficit and the levels of extracellular low-molecular mass oligomers (Figures 3C, 4C) . Similarly, WT GFP BMC transplantation reduced membrane-associated Aβ levels, particularly the 3-mer ( Figures 3D, E , and 4D, E, respectively), whereas CCR2 -/-cell transplantation in APP Swe / PS1 mice caused an increase of 2-and 3-mer levels compared with the control group GFP → APP Swe /PS1 mice ( Figures 3D, E) . However, no correlation was found between cognitive deficit and Aβ oligomers associated with membrane, except for fulllength APP (APPfl) ( Figure 3F ). Transplantation of GFP or CCR2 -/-cells had no effect on soluble intracellular Aβ oligomers in APP Swe / PS1 and APP Swe / PS1/ CCR2 -/-mice ( Figure 5 ). In conclusion, competent CCR2 HSCs are able to control Aβ production and/or clearance. . Lower levels of soluble extracellular and membrane-associated Aβ species were found in mice harboring WT BMCs, whereas Aβ oligomer levels increased in mice transplanted with CCR2-deficient BMCs. Correlations were determined between spatial memory decline (water T-maze test) and soluble Aβ species in extracellular (C) and membrane-associated (F) fractions. Results are expressed as the mean ± SEM; n = 4-5; *P < 0.05 and **P < 0. To assess whether transplantation of BMCs influences leukocyte levels, monocyte frequency and the distribution of the Gr1 status in the population was determined by FACS analysis. Interestingly, monocyte frequency was significantly higher in mice that were transplanted with WT BMCs than in mice receiving CCR2-deficient cells (Figure 8) 
Cytokine Gene Expression in the Brain
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Monocytes in CCR2 -/-Mice
To further investigate the role of the CCR2-competent BMCs, we injected lenti-GFP-CCR2 or its control lenti-GFP in the femoral cavity of nonirradiated APP Swe / PS1 and APP Swe /PS1/CCR2 -/-mice. Three months later, lenti-GFP-CCR2-treated mice exhibited a significant improvement of their spatial learning memory during the water T-maze test (Figures 9B, D) . Interestingly, CCR2 overexpression in BMCs of the APP Swe / PS1 also prevented the apparition of the spatial learning deficit. FACS analyses revealed that GFP protein is expressed by <1% leukocytes at 2 months and almost 2% at 3 months after femoral injections ( Figure 9E ). Detailed analysis of leukocyte population provided evidence that monocytes preferentially expressed the lentiviral construction with the CCR2 transgene (see Figure 9E ). More importantly, CCR2-GFP microglia were found in the vicinity of senile plaques in the hippocampus ( Figure 9H ) and cerebral cortex of nonirradiated APP Swe /PS1/ CCR2 -/-mice ( Figures 9F, G) . A detailed analysis of the monocytic population showed that intrafemorally injected lenti-GFP-CCR2 increased CCR2 expression in monocytes of CCR2 -/-mice (2.08 ± 0.06% versus 1.25 ± 0.21% of monocytes in lenti-GFP-injected CCR2 -/-mice; P < 0.05, Figure 10H ). Four weeks after intrafemoral injection, CCR2 was expressed in the circulating CD11b 
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DISCUSSION
We previously demonstrated that CCR2 deficiency in a mouse model of AD accelerates disease onset and aggravates mnesic deficits (37) . Here we show that transplantation of CCR2-deficient BMCs D 1 8 : 2 9 7 -3 1 3 , 2 0 1 2 Figure 6 . Expression of TGF-β1, and of TGF-β-R1 and -R2, mRNA in the brain of APP Swe /PS1 mice transplanted with WT (GFP) or CCR2-deficient BMCs. Representative dark-field photomicrographs of in situ hybridization are shown of the cortical expression of TGF-β1 (left panels), TGF-β-R1 (middle panels) and TGF-β-R2 mRNA (right panels) in 6-month-old APP Swe /PS1 and APP Swe /PS1/CCR2 -/-harboring bone marrow GFP or CCR2 -/-cells. Qualitative quantification was performed for each transcript (n = 5-12) (M). A decrease in TGF-β1, and in TGF-β-R1 and -R2, mRNA levels was found in the brain of mice transplanted with WT GFP cells. Scale bar 500 μm. M: The plus signs correspond to the intensity and the surface of the signal. The number of the plus signs shows augment proportionally with the intensity and the surface.
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in APP Swe /PS1 mice causes similar effects: APP Swe /PS1/CCR2 -/-mice and APP Swe /PS1 mice harboring CCR2-deficient BMCs exhibit significant spatial and contextual memory impairments. Moreover, cognitive capacities are restored in APP Swe /PS1 and APP Swe /PS1/ CCR2 -/-mice after transplantation of WT GFP BMCs or the expression of lentivirus-induced CCR2 in the bone marrow. It is important to note that APP Swe /PS1/CCR2 -/-mice already exhibited mnesic impairments and increased levels of soluble Aβ at the age of transplantation (2.5-3 months). Such defects are normally detected only at 6 months of age in APP Swe /PS1 mice, suggesting that transplantation of WT BMCs does not only prevent the onset of the disease, but also cures the pathology in this mouse model of AD. These data provide solid evidence of the beneficial effect of CCR2-expressing BMCs in AD. Moreover, the rescue of mnesic capacity by WT BMC transplantation in APP Swe / PS1 mice suggests a defect of hematopoietic system in a context of APP production. The ability of an intrafemoral injection of lenti-CCR2 to restore the cognitive capacity of APP Swe /PS1 mice further supports an impairment of CCR2 expression/function in the BMCs of these mice. In AD brains, Aβ can accumulate as both soluble and insoluble assemblies, and the correlation between parenchymal Aβ deposits (that is, insoluble Aβ) and the degree of cognitive impairment is no longer supported by strong evidence. Levels of smaller soluble Aβ oligomers correlate more strongly with memory decline in the brains of both AD patients (46, 47) and mouse models of AD (1, 48, 50) . In the present study, transplantation of WT or CCR2 -/-BMCs in APP Swe /PS1 and APP Swe /PS1/CCR2 -/-mice had no effect on Aβ deposition when compared with control littermates. In contrast, transplantation of WT BMCs reduced the levels of small Aβ oligomers (6-, 3-, 2-and 1-mers) in extracellular-and membrane-associated proteins, concomitantly with a rescue of mnesic deficits in both groups of APP Swe / PS1 and APP Swe /PS1/CCR2 -/-chimeric BMCs. These small soluble oligomers can disrupt learning behavior (51) , are toxic for neurons and disrupt synaptic plasticity by binding to lipid membranes (52) (53) (54) . In AD patients, levels of soluble intracellular and membrane-associated Aβ in the temporal neocortex seem more closely related to AD symptoms than other measured Aβ species (55) . Once again, our results are in line with the recent hypothesis that memory deficits correlate more strongly with cortical levels of soluble Aβ species than with insoluble Aβ plaque burden. The potential mechanisms mediating the clearance of soluble Aβ by competent myeloid cells are numerous and might involve Aβ turnover, since CCR2 deficiency decreased the expression of neprilysin (Mme, a major Aβ-degrading enzyme) in the brain of AD mice (36) . Bone marrow-derived microglial cells have the ability to phagocytize Aβ, and oligomeric, protofibrillar and fibrillar amyloid can be removed by microglia depending on the context (45, (56) (57) (58) (59) . Although HSC-derived monocytic cells share common characteristics with microglia and peripheral monocytes, they reduce Aβ faster than microglia (60) . These bone marrow-derived cells infiltrate into nonirradiated brain (61) suggesting that CCR2-deficient microglia do not phagocytize and clear soluble Aβ. Actually, disruption of Aβ clearance by microglia is probably the most important mechanism accounting for the accumulation of Aβ in a context of CCR2 deficiency. CCR2 deficiency in APP Swe /PS1 mice was associated with higher CX 3 CR1 expression levels in plaqueassociated microglia concomitantly with enhanced levels of soluble Aβ (37) . This result could explain the inability of CCR2 -/-bone marrow-derived microglia to clear Aβ, since CX 3 CR1/CX 3 CL1 signaling strongly inhibits microglia activation and their phagocytic capacities (57, 58) . These effects could be also mediated by TGF-β1, since APP Swe /PS1 mice harboring CCR2 -/-BMCs exhibited enhanced expression of TGF-β1 and TGF-β-R1 and -R2 transcript levels in plaque-associated microglia. A drastic decrease in TGF-β1 and its receptor levels was found in microglia surrounding Aβ plaques in APP Swe /PS1 and APP Swe / PS1/ CCR2 -/-mice transplanted with WT GFP cells. Although the exact role played by TGF-β1 in the physiopathology of AD is still debated today, accumulating evidence confirms its contribution to the progression of disease. In vitro, TGF-β1 binds Aβ with high affinity and induces Aβ oligomerization (62) , whereas in the brain, TGF-β1 reduced microglial activation (63) . TGF-β1 overexpression accelerates and promotes amyloidogenesis in mouse models of AD (64) (65) (66) , and interruption of TGF-β1 signaling in BMderived microglia/macrophages mitigates cognitive impairment and attenuates amyloidosis in AD mice (67) . Therefore, TGF-β1 could act directly on microglia to diminish their phagocytic properties, prevent Aβ clearance and then increase Aβ production and oligomerization, which would aggravate memory deficits and accelerate disease progression. Here, again, a detrimental role of the TGF-β system was supported in the cognitive impairment and Aβ accumulation features, since diminution of brain soluble Aβ levels and restoration of as well as in APP Swe /PS1 mice. Interestingly, lenti-GFP-CCR2-treated mice had performances similar to WT mice. Results are expressed as the mean ± SEM; n = 6-13; **P < 0.01 and ***P < 0.001 versus no treatment; ## P < 0.01 versus lenti-GFP . Two-way ANOVA was performed and revealed no interaction between the various genotypes and treatments. Bonferroni or Tamhane tests were used for post hoc comparisons. Blood cells were analyzed by FACS, and GFP expression was detected in leukocytes 2 and 3 months after lenti-GFP or lenti-GFP-CCR2 intrafemoral injection (E). Among the various leukocyte populations, GFP protein was preferentially expressed in monocytes. Results are expressed as the mean ± SEM; n = 4-6. BMCs transduced with lenti-CCR2 infiltrated the brain parenchyma of nonirradiated APP Swe / PS1/CCR2 -/-mice, as depicted by confocal photomicrographs of the cerebral cortex (F, G) and hippocampus (H It was proposed that cerebral Aβ is cleared across the blood-brain barrier, based on the findings of active Aβ transport from the brain into the periphery via the low-density lipoprotein receptor (LRP-1) (68) and from the periphery into brain through the receptor for advanced glycation end products (69, 70) . The peripheral sink hypothesis proposes that a reduction of free Aβ levels in the blood enhances the transport of Aβ from the brain and then contributes to reduce the Aβ load in the brain (71) (72) (73) . There is evidence for a dysfunctional brain-to-blood Aβ clearance in AD patients and in transgenic mouse models of the disease (70, 71 
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CONCLUSION
In conclusion, we have demonstrated that CCR2 deficiency specifically in HSCs of AP PSw e/PS1 mice provokes a rapid cognitive decline that closely correlates with the accumulation of soluble Αb oligomers in the brain and with robust mRNA expression of TGF−b1 and its receptor TGF−b-R2 in C X 3CR1-positive microglia. Rescue of CCR2 expression in BMCs provides direct evidence that CCR2-competent bone marrow-derived microglia can restrict Αb toxicity and restore cognitive functions. The complementary approaches used in this study support a neuroprotective role for CCR2-competent monocytes in the physiopathology of AD. We propose that such innate immune mechanisms may be deficient or suboptimal in AD patients; therefore, gene therapy upregulating CCR2 gene expression in HSCs is likely to provide a novel treatment with great potential in the near future. A similar approach using lentiviral-mediated gene therapy of HSCs was recently used with great success in two 7-year-old boys suffering from a rare and fatal demyelinating brain disease (74) .
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